摘要目的 了解我国PET/CT使用实际状况,为推广PET/CT提供数据.方法 收集10家三甲医院PET/CT中心2006年6月-8月共3018例PET/CT受检者资料进行分析.结果 (1)检查目的:诊断肿瘤、体格检查和其他目的的受检者构成比分别为63.0%,32.9%和4.1%.(2)诊断:PET/CT诊断恶性肿瘤的真阳性率93.5%;PET/CT为38.6%的单纯转移癌受检者找到原发灶;在病理检查结果为良性病变,但临床仍要求鉴别占位性病变良恶性的受检者中,PET/CT发现23.3%的受检查者有恶性肿瘤.(3)受检者个人情况:不同月收入受检者例数前3位的组内构成比:＞6000元者30.4%,4001～6000元者28.8%,2001～4000元者18.6%;不同医疗社会保障受检者例数前3位的组内构成比:自费医疗者55.6%,国家基本医疗保险者26.5%,公费医疗者11.4%;不同职业受检者例数前3位的组内构成比:机关事业单位工作人员21.9%,退休人员15.6%,企业领导11.8%;不同受教育程度受检者例数前3位的组内构成比:大学(含大专)48.2%,高中(含中专或技校)21.3%,初中13.8%.结论 PET/CT在肿瘤学中有重要的临床应用价值.如何充分利用现有资源,充分发挥其效益是亟待解决的问题.

abstractsObjective The aim of this study was to analyze the current practical status of PET/CT application in China and for provision of data in support of promoting the utility of this imaging modality.Methods All 3018 PET/CT cases from 10 hospitals in the top 3 rankings were recruited in the data analysis from June to August,2006.Results(1)Reason for referral:the proportions of patients referred for oncologic diagnosis,check-up and other reasons were 63.0%,32.9% and 4.1%,respectively.(2)Diagnosis:PET/CT had a 93.5% true positive value in diagnosing malignant tumors,38.6% success rate in identifying the primary malignancy in patients presented with metastases.and 23.3% discovery rate of malignancy in patients with space-occupying lesions pathologically diagnosed as benign but clinically requested to differentiate between benignity and malignancy.(3)Patient data:the proportion of patients in the top 3 income groups(monthly)was:＞$6000,30.4%;$4001-6000,28.8%;and $2001-4000,18.6%.The proportion of patients in the top 3 medical insurance or security category:self-paid or uninsured,55.6%;national basic insurance scheme,26.5%;public paid fund,11.4%.The top 3 groups of patients catego rized according to profession were:departmental officials,21.9%;retiree,15.6%;company leaders,11.8%.The top 3 groups according to level of education were:university(including college),48.2%;high school(including technical training schools),21.3%;primary school,13.8%.Conclusions PET/CT holds an essential clinical value in oncology.It is an utmost issue on how to fully utilize the existing resources with a purpose to achieve maximal benefit and return.